Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Dilated cardiomyopathy (DCM) is a particular phenotype of non-ischemic systolic heart failure, frequently recognizing a genetic background and affecting relatively young patients with few comorbidities. Nowadays, long-term survival of DCM patients has been markedly improved due to an early diagnosis and uninterrupted and tailored follow-up under constant optimal medical and non-pharmacological evidence-based treatments. Nevertheless, DCM is still one of the most common causes of heart transplantation in the western world. Clinical management requires an integrated and systematic use of diagnostic tools and a deeper investigation of the basic mechanisms underlying the disease. However, several emerging issues remain debated. Specifically, the genotype–phenotype correlation, the role of advanced imaging techniques and genetic testing, the lack of appropriate risk stratification models, the need for a multiparametric and multidisciplinary approach for device implantation, and a continuous reclassification of the disease during follow-up remain challenging issues in clinical practice. Therefore, the aim of this Special Issue is to shed the light on the most recent advancements in characterization and clinical management of DCM in order to unveil the conundrum of this particular disease.
SCN5A --- cardiac sodium channel --- cardiac channelopathy --- dilated cardiomyopathy --- precision medicine --- arrhythmias --- atrial fibrillation --- cardiomyopathy --- heart failure --- supraventricular arrhythmia --- systolic dysfunction --- tachycardiomyopathy --- ventricular arrhythmia --- left atrial strain --- cardiac resynchronization therapy --- muscular dystrophy --- calcium --- heart --- gene therapy --- phospholamban --- Serca2a --- mdx --- oxidative stress --- membrane stabilization --- left ventricular noncompaction --- congenital heart disease --- congestive heart failure --- non-ischemic cardiomyopathy --- genetics --- desmin --- mitochondrial dysfunction --- myopathy --- whole exome sequencing --- laminopathy --- LMNA --- biomarkers --- troponin T --- NT-proBNP --- malignant ventricular arrhythmia --- arrhythmic risk stratification --- DNA methylation --- alternative splicing --- epigenetics --- nonischemic dilated cardiomyopathy --- cardiac magnetic resonance imaging --- late gadolinium enhancement --- long axis strain --- left ventricle sphericity index --- major adverse cardiovascular events --- sex differences --- left ventricular reverse remodelling --- long-term outcomes --- left ventricle non-compaction cardiomyopathy --- cardiac magnetic resonance --- titin --- RNA binding motif protein 20 (RBM20) --- sarcomere --- diastolic dysfunction --- phosphorylation --- non-sense mRNA decay --- mammalian target of rapamycin (mTOR) complex-1 --- duchenne muscular distrophy --- n/a
Choose an application
Dilated cardiomyopathy (DCM) is a particular phenotype of non-ischemic systolic heart failure, frequently recognizing a genetic background and affecting relatively young patients with few comorbidities. Nowadays, long-term survival of DCM patients has been markedly improved due to an early diagnosis and uninterrupted and tailored follow-up under constant optimal medical and non-pharmacological evidence-based treatments. Nevertheless, DCM is still one of the most common causes of heart transplantation in the western world. Clinical management requires an integrated and systematic use of diagnostic tools and a deeper investigation of the basic mechanisms underlying the disease. However, several emerging issues remain debated. Specifically, the genotype–phenotype correlation, the role of advanced imaging techniques and genetic testing, the lack of appropriate risk stratification models, the need for a multiparametric and multidisciplinary approach for device implantation, and a continuous reclassification of the disease during follow-up remain challenging issues in clinical practice. Therefore, the aim of this Special Issue is to shed the light on the most recent advancements in characterization and clinical management of DCM in order to unveil the conundrum of this particular disease.
Medicine --- SCN5A --- cardiac sodium channel --- cardiac channelopathy --- dilated cardiomyopathy --- precision medicine --- arrhythmias --- atrial fibrillation --- cardiomyopathy --- heart failure --- supraventricular arrhythmia --- systolic dysfunction --- tachycardiomyopathy --- ventricular arrhythmia --- left atrial strain --- cardiac resynchronization therapy --- muscular dystrophy --- calcium --- heart --- gene therapy --- phospholamban --- Serca2a --- mdx --- oxidative stress --- membrane stabilization --- left ventricular noncompaction --- congenital heart disease --- congestive heart failure --- non-ischemic cardiomyopathy --- genetics --- desmin --- mitochondrial dysfunction --- myopathy --- whole exome sequencing --- laminopathy --- LMNA --- biomarkers --- troponin T --- NT-proBNP --- malignant ventricular arrhythmia --- arrhythmic risk stratification --- DNA methylation --- alternative splicing --- epigenetics --- nonischemic dilated cardiomyopathy --- cardiac magnetic resonance imaging --- late gadolinium enhancement --- long axis strain --- left ventricle sphericity index --- major adverse cardiovascular events --- sex differences --- left ventricular reverse remodelling --- long-term outcomes --- left ventricle non-compaction cardiomyopathy --- cardiac magnetic resonance --- titin --- RNA binding motif protein 20 (RBM20) --- sarcomere --- diastolic dysfunction --- phosphorylation --- non-sense mRNA decay --- mammalian target of rapamycin (mTOR) complex-1 --- duchenne muscular distrophy --- SCN5A --- cardiac sodium channel --- cardiac channelopathy --- dilated cardiomyopathy --- precision medicine --- arrhythmias --- atrial fibrillation --- cardiomyopathy --- heart failure --- supraventricular arrhythmia --- systolic dysfunction --- tachycardiomyopathy --- ventricular arrhythmia --- left atrial strain --- cardiac resynchronization therapy --- muscular dystrophy --- calcium --- heart --- gene therapy --- phospholamban --- Serca2a --- mdx --- oxidative stress --- membrane stabilization --- left ventricular noncompaction --- congenital heart disease --- congestive heart failure --- non-ischemic cardiomyopathy --- genetics --- desmin --- mitochondrial dysfunction --- myopathy --- whole exome sequencing --- laminopathy --- LMNA --- biomarkers --- troponin T --- NT-proBNP --- malignant ventricular arrhythmia --- arrhythmic risk stratification --- DNA methylation --- alternative splicing --- epigenetics --- nonischemic dilated cardiomyopathy --- cardiac magnetic resonance imaging --- late gadolinium enhancement --- long axis strain --- left ventricle sphericity index --- major adverse cardiovascular events --- sex differences --- left ventricular reverse remodelling --- long-term outcomes --- left ventricle non-compaction cardiomyopathy --- cardiac magnetic resonance --- titin --- RNA binding motif protein 20 (RBM20) --- sarcomere --- diastolic dysfunction --- phosphorylation --- non-sense mRNA decay --- mammalian target of rapamycin (mTOR) complex-1 --- duchenne muscular distrophy
Choose an application
Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.
Medicine --- diet quality --- ceramides --- obesity --- cardiovascular risk --- healthy eating index --- carbohydrate antigen-125 --- heart failure --- inflammatory marker --- older women --- biomarker --- cardiometabolic disease --- epicardial adipose tissue --- epicardial fat --- epicardial fat volume --- microRNA --- thyroid-stimulating hormone --- cardiometabolic risks --- metabolic syndrome --- hypertension --- very low-density lipoprotein --- STIM1 --- SOCE --- atrial myopathy --- atrial fibrillation --- ejection fraction --- soluble urokinase-type plasminogen activator receptor (suPAR) --- growth differentiation factor 15 (GDF-15) --- heart-type fatty acid-binding protein (H-FABP) --- soluble suppression of tumorigenicity 2 (sST2) --- acute myocardial infarction --- biomarkers --- catestatin --- coronary artery disease --- heart failure decompensation --- left ventricular ejection fraction --- troponin --- NT-proBNP --- NYHA functional class --- GDF-15 --- cardiovascular surgery --- operative risk --- muscle wasting --- sarcopenia --- renal dysfunction --- chronic kidney disease --- aortic disease --- aneurysm --- miRNA --- TGF-β pathway --- KLF4 --- synthetic phenotype --- aortic regurgitation --- echocardiography --- magnetic resonance imaging --- vena contracta area --- longitudinal strain --- T1 mapping --- GDF8 --- myostatin --- AMI --- ceruloplasmin --- H-FABP --- heart-type fatty acid-binding protein --- FABP3 --- fatty acid-binding protein 3 --- HF --- cardiac biomarkers --- cardiac magnetic resonance imaging --- left ventricular systolic function --- magnetic resonance spectroscopy --- myocardial triglyceride content --- cell adhesion molecule --- repeated measurements --- pregnancy-associated plasma protein-A --- cohort studies --- cardiovascular diseases --- mitochondrial dysfunction --- circulating cells --- PBMCS --- platelets --- oxidative stress --- reactive oxygen species (ROS) --- mitochondrial DNA (mtDNA) --- herat failure --- liver-type fatty-acid-binding protein --- long-term outcomes --- cardiac intensive care units --- acute kidney injury --- myocardial infarction --- STEMI --- cardiovascular events --- cardiovascular death --- risk stratification --- sST2 --- Pentraxin-3 --- sudden cardiac death --- ventricular arrhythmia --- ventricular tachycardia --- chronic heart failure --- saliva --- salivary biomarkers --- CKD --- CVD --- PPCI --- left ventricular adverse remodelling --- circulating miRNAs --- NAFLD --- Framingham risk score --- risk prediction --- secondary prevention --- primary prevention --- NAFLD fibrosis score --- HFpEF --- HFrEF --- suPAR --- diet quality --- ceramides --- obesity --- cardiovascular risk --- healthy eating index --- carbohydrate antigen-125 --- heart failure --- inflammatory marker --- older women --- biomarker --- cardiometabolic disease --- epicardial adipose tissue --- epicardial fat --- epicardial fat volume --- microRNA --- thyroid-stimulating hormone --- cardiometabolic risks --- metabolic syndrome --- hypertension --- very low-density lipoprotein --- STIM1 --- SOCE --- atrial myopathy --- atrial fibrillation --- ejection fraction --- soluble urokinase-type plasminogen activator receptor (suPAR) --- growth differentiation factor 15 (GDF-15) --- heart-type fatty acid-binding protein (H-FABP) --- soluble suppression of tumorigenicity 2 (sST2) --- acute myocardial infarction --- biomarkers --- catestatin --- coronary artery disease --- heart failure decompensation --- left ventricular ejection fraction --- troponin --- NT-proBNP --- NYHA functional class --- GDF-15 --- cardiovascular surgery --- operative risk --- muscle wasting --- sarcopenia --- renal dysfunction --- chronic kidney disease --- aortic disease --- aneurysm --- miRNA --- TGF-β pathway --- KLF4 --- synthetic phenotype --- aortic regurgitation --- echocardiography --- magnetic resonance imaging --- vena contracta area --- longitudinal strain --- T1 mapping --- GDF8 --- myostatin --- AMI --- ceruloplasmin --- H-FABP --- heart-type fatty acid-binding protein --- FABP3 --- fatty acid-binding protein 3 --- HF --- cardiac biomarkers --- cardiac magnetic resonance imaging --- left ventricular systolic function --- magnetic resonance spectroscopy --- myocardial triglyceride content --- cell adhesion molecule --- repeated measurements --- pregnancy-associated plasma protein-A --- cohort studies --- cardiovascular diseases --- mitochondrial dysfunction --- circulating cells --- PBMCS --- platelets --- oxidative stress --- reactive oxygen species (ROS) --- mitochondrial DNA (mtDNA) --- herat failure --- liver-type fatty-acid-binding protein --- long-term outcomes --- cardiac intensive care units --- acute kidney injury --- myocardial infarction --- STEMI --- cardiovascular events --- cardiovascular death --- risk stratification --- sST2 --- Pentraxin-3 --- sudden cardiac death --- ventricular arrhythmia --- ventricular tachycardia --- chronic heart failure --- saliva --- salivary biomarkers --- CKD --- CVD --- PPCI --- left ventricular adverse remodelling --- circulating miRNAs --- NAFLD --- Framingham risk score --- risk prediction --- secondary prevention --- primary prevention --- NAFLD fibrosis score --- HFpEF --- HFrEF --- suPAR
Choose an application
In recent years, artificial intelligence has increasingly been playing an essential role in diverse areas in medicine, assisting clinicians in patient management. In nephrology and transplantation, artificial intelligence can be utilized to enhance clinical care, such as through hemodialysis prescriptions and the follow-up of kidney transplant patients. Furthermore, there are rapidly expanding applications and validations of comprehensive, computerized medical records and related databases, including national registries, health insurance, and drug prescriptions. For this Special Issue, we made a call to action to stimulate researchers and clinicians to submit their invaluable works and present, here, a collection of articles covering original clinical research (single- or multi-center), database studies from registries, meta-analyses, and artificial intelligence research in nephrology including acute kidney injury, electrolytes and acid–base, chronic kidney disease, glomerular disease, dialysis, and transplantation that will provide additional knowledge and skills in the field of nephrology and transplantation toward improving patient outcomes.
Medicine --- tacrolimus --- C/D ratio --- tacrolimus metabolism --- everolimus --- conversion --- kidney transplantation --- gut microbiome --- renal transplant recipient --- diarrhea --- immunosuppressive medication --- gut microbiota --- 16S rRNA sequencing --- butyrate-producing bacteria --- Proteobacteria --- torquetenovirus --- immunosuppression --- transplantation --- immunosuppressed host --- outcome --- renal transplantation --- Goodpasture syndrome --- anti-GBM disease --- epidemiology --- hospitalization --- outcomes --- acute kidney injury --- risk prediction --- artificial intelligence --- patent ductus arteriosus --- conservative management --- blood pressure --- eradication --- interferon-free regimen --- hepatitis C infection --- kidney transplant --- allograft steatosis --- lipopeliosis --- transplant numbers --- live donors --- public awareness --- Google TrendsTM --- machine learning --- big data --- nephrology --- chronic kidney disease --- NLR --- PLR --- RPGN --- predictive value --- hemodialysis --- withdrawal --- cellular crescent --- global sclerosis --- procurement kidney biopsy --- glomerulosclerosis --- minimally-invasive donor nephrectomy --- robot-assisted surgery --- laparoscopic surgery --- organ donation --- living kidney donation --- MeltDose® --- LCPT --- renal function --- liver transplantation --- metabolism --- erythropoietin --- fibroblast growth factor 23 --- death --- weekend effect --- in-hospital mortality --- comorbidity --- dialysis --- elderly --- klotho --- α-Klotho --- FGF-23 --- kidney donor --- Nephrology --- CKD-MBD --- CKD-Mineral and Bone Disorder --- deceased donor --- Eurotransplant Senior Program --- risk stratification --- intensive care --- kidney transplant recipients --- long-term outcomes --- graft failure --- cardiovascular mortality --- lifestyle --- inflammation --- vascular calcification --- bone mineral density --- dual-energy X-ray absorptiometry --- living donation --- repeated kidney transplantation --- graft survival --- prolonged ischaemic time --- patient survival --- pre-emptive transplantation --- metabolomics --- urine --- acute rejection --- allograft --- cystatin C --- hyperfiltration --- kidney injury molecule (KIM)-1 --- tubular damage --- genetic polymorphisms --- (cardiac) surgery --- inflammatory cytokines --- clinical studies --- chronic kidney disease (CKD) --- no known kidney disease (NKD) --- ICD-10 billing codes --- phenotyping --- electronic health record (EHR) --- estimated glomerular filtration rate (eGFR) --- machine learning (ML) --- generalized linear model network (GLMnet) --- random forest (RF) --- artificial neural network (ANN), clinical natural language processing (clinical NLP) --- discharge summaries --- laboratory values --- area under the receiver operating characteristic (AUROC) --- area under the precision-recall curve (AUCPR) --- fibrosis --- extracellular matrix --- collagen type VI --- living-donor kidney transplantation --- ethnic disparity --- tacrolimus --- C/D ratio --- tacrolimus metabolism --- everolimus --- conversion --- kidney transplantation --- gut microbiome --- renal transplant recipient --- diarrhea --- immunosuppressive medication --- gut microbiota --- 16S rRNA sequencing --- butyrate-producing bacteria --- Proteobacteria --- torquetenovirus --- immunosuppression --- transplantation --- immunosuppressed host --- outcome --- renal transplantation --- Goodpasture syndrome --- anti-GBM disease --- epidemiology --- hospitalization --- outcomes --- acute kidney injury --- risk prediction --- artificial intelligence --- patent ductus arteriosus --- conservative management --- blood pressure --- eradication --- interferon-free regimen --- hepatitis C infection --- kidney transplant --- allograft steatosis --- lipopeliosis --- transplant numbers --- live donors --- public awareness --- Google TrendsTM --- machine learning --- big data --- nephrology --- chronic kidney disease --- NLR --- PLR --- RPGN --- predictive value --- hemodialysis --- withdrawal --- cellular crescent --- global sclerosis --- procurement kidney biopsy --- glomerulosclerosis --- minimally-invasive donor nephrectomy --- robot-assisted surgery --- laparoscopic surgery --- organ donation --- living kidney donation --- MeltDose® --- LCPT --- renal function --- liver transplantation --- metabolism --- erythropoietin --- fibroblast growth factor 23 --- death --- weekend effect --- in-hospital mortality --- comorbidity --- dialysis --- elderly --- klotho --- α-Klotho --- FGF-23 --- kidney donor --- Nephrology --- CKD-MBD --- CKD-Mineral and Bone Disorder --- deceased donor --- Eurotransplant Senior Program --- risk stratification --- intensive care --- kidney transplant recipients --- long-term outcomes --- graft failure --- cardiovascular mortality --- lifestyle --- inflammation --- vascular calcification --- bone mineral density --- dual-energy X-ray absorptiometry --- living donation --- repeated kidney transplantation --- graft survival --- prolonged ischaemic time --- patient survival --- pre-emptive transplantation --- metabolomics --- urine --- acute rejection --- allograft --- cystatin C --- hyperfiltration --- kidney injury molecule (KIM)-1 --- tubular damage --- genetic polymorphisms --- (cardiac) surgery --- inflammatory cytokines --- clinical studies --- chronic kidney disease (CKD) --- no known kidney disease (NKD) --- ICD-10 billing codes --- phenotyping --- electronic health record (EHR) --- estimated glomerular filtration rate (eGFR) --- machine learning (ML) --- generalized linear model network (GLMnet) --- random forest (RF) --- artificial neural network (ANN), clinical natural language processing (clinical NLP) --- discharge summaries --- laboratory values --- area under the receiver operating characteristic (AUROC) --- area under the precision-recall curve (AUCPR) --- fibrosis --- extracellular matrix --- collagen type VI --- living-donor kidney transplantation --- ethnic disparity
Choose an application
In recent years, artificial intelligence has increasingly been playing an essential role in diverse areas in medicine, assisting clinicians in patient management. In nephrology and transplantation, artificial intelligence can be utilized to enhance clinical care, such as through hemodialysis prescriptions and the follow-up of kidney transplant patients. Furthermore, there are rapidly expanding applications and validations of comprehensive, computerized medical records and related databases, including national registries, health insurance, and drug prescriptions. For this Special Issue, we made a call to action to stimulate researchers and clinicians to submit their invaluable works and present, here, a collection of articles covering original clinical research (single- or multi-center), database studies from registries, meta-analyses, and artificial intelligence research in nephrology including acute kidney injury, electrolytes and acid–base, chronic kidney disease, glomerular disease, dialysis, and transplantation that will provide additional knowledge and skills in the field of nephrology and transplantation toward improving patient outcomes.
tacrolimus --- C/D ratio --- tacrolimus metabolism --- everolimus --- conversion --- kidney transplantation --- gut microbiome --- renal transplant recipient --- diarrhea --- immunosuppressive medication --- gut microbiota --- 16S rRNA sequencing --- butyrate-producing bacteria --- Proteobacteria --- torquetenovirus --- immunosuppression --- transplantation --- immunosuppressed host --- outcome --- renal transplantation --- Goodpasture syndrome --- anti-GBM disease --- epidemiology --- hospitalization --- outcomes --- acute kidney injury --- risk prediction --- artificial intelligence --- patent ductus arteriosus --- conservative management --- blood pressure --- eradication --- interferon-free regimen --- hepatitis C infection --- kidney transplant --- allograft steatosis --- lipopeliosis --- transplant numbers --- live donors --- public awareness --- Google TrendsTM --- machine learning --- big data --- nephrology --- chronic kidney disease --- NLR --- PLR --- RPGN --- predictive value --- hemodialysis --- withdrawal --- cellular crescent --- global sclerosis --- procurement kidney biopsy --- glomerulosclerosis --- minimally-invasive donor nephrectomy --- robot-assisted surgery --- laparoscopic surgery --- organ donation --- living kidney donation --- MeltDose® --- LCPT --- renal function --- liver transplantation --- metabolism --- erythropoietin --- fibroblast growth factor 23 --- death --- weekend effect --- in-hospital mortality --- comorbidity --- dialysis --- elderly --- klotho --- α-Klotho --- FGF-23 --- kidney donor --- Nephrology --- CKD-MBD --- CKD-Mineral and Bone Disorder --- deceased donor --- Eurotransplant Senior Program --- risk stratification --- intensive care --- kidney transplant recipients --- long-term outcomes --- graft failure --- cardiovascular mortality --- lifestyle --- inflammation --- vascular calcification --- bone mineral density --- dual-energy X-ray absorptiometry --- living donation --- repeated kidney transplantation --- graft survival --- prolonged ischaemic time --- patient survival --- pre-emptive transplantation --- metabolomics --- urine --- acute rejection --- allograft --- cystatin C --- hyperfiltration --- kidney injury molecule (KIM)-1 --- tubular damage --- genetic polymorphisms --- (cardiac) surgery --- inflammatory cytokines --- clinical studies --- chronic kidney disease (CKD) --- no known kidney disease (NKD) --- ICD-10 billing codes --- phenotyping --- electronic health record (EHR) --- estimated glomerular filtration rate (eGFR) --- machine learning (ML) --- generalized linear model network (GLMnet) --- random forest (RF) --- artificial neural network (ANN), clinical natural language processing (clinical NLP) --- discharge summaries --- laboratory values --- area under the receiver operating characteristic (AUROC) --- area under the precision-recall curve (AUCPR) --- fibrosis --- extracellular matrix --- collagen type VI --- living-donor kidney transplantation --- ethnic disparity
Choose an application
Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.
diet quality --- ceramides --- obesity --- cardiovascular risk --- healthy eating index --- carbohydrate antigen-125 --- heart failure --- inflammatory marker --- older women --- biomarker --- cardiometabolic disease --- epicardial adipose tissue --- epicardial fat --- epicardial fat volume --- microRNA --- thyroid-stimulating hormone --- cardiometabolic risks --- metabolic syndrome --- hypertension --- very low-density lipoprotein --- STIM1 --- SOCE --- atrial myopathy --- atrial fibrillation --- ejection fraction --- soluble urokinase-type plasminogen activator receptor (suPAR) --- growth differentiation factor 15 (GDF-15) --- heart-type fatty acid-binding protein (H-FABP) --- soluble suppression of tumorigenicity 2 (sST2) --- acute myocardial infarction --- biomarkers --- catestatin --- coronary artery disease --- heart failure decompensation --- left ventricular ejection fraction --- troponin --- NT-proBNP --- NYHA functional class --- GDF-15 --- cardiovascular surgery --- operative risk --- muscle wasting --- sarcopenia --- renal dysfunction --- chronic kidney disease --- aortic disease --- aneurysm --- miRNA --- TGF-β pathway --- KLF4 --- synthetic phenotype --- aortic regurgitation --- echocardiography --- magnetic resonance imaging --- vena contracta area --- longitudinal strain --- T1 mapping --- GDF8 --- myostatin --- AMI --- ceruloplasmin --- H-FABP --- heart-type fatty acid-binding protein --- FABP3 --- fatty acid-binding protein 3 --- HF --- cardiac biomarkers --- cardiac magnetic resonance imaging --- left ventricular systolic function --- magnetic resonance spectroscopy --- myocardial triglyceride content --- cell adhesion molecule --- repeated measurements --- pregnancy-associated plasma protein-A --- cohort studies --- cardiovascular diseases --- mitochondrial dysfunction --- circulating cells --- PBMCS --- platelets --- oxidative stress --- reactive oxygen species (ROS) --- mitochondrial DNA (mtDNA) --- herat failure --- liver-type fatty-acid-binding protein --- long-term outcomes --- cardiac intensive care units --- acute kidney injury --- myocardial infarction --- STEMI --- cardiovascular events --- cardiovascular death --- risk stratification --- sST2 --- Pentraxin-3 --- sudden cardiac death --- ventricular arrhythmia --- ventricular tachycardia --- chronic heart failure --- saliva --- salivary biomarkers --- CKD --- CVD --- PPCI --- left ventricular adverse remodelling --- circulating miRNAs --- NAFLD --- Framingham risk score --- risk prediction --- secondary prevention --- primary prevention --- NAFLD fibrosis score --- HFpEF --- HFrEF --- suPAR --- n/a
Listing 1 - 6 of 6 |
Sort by
|